DDrare: Database of Drug Development for Rare Diseases

95. 自己免疫性肝炎
［臨床試験数：44，薬物数：57（DrugBank：26），標的遺伝子数：18，標的パスウェイ数：108］

Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZATHIOPRINE; Abatacept; Anti-BAFFR antibody; Anti-BAFFr antibody; Azathioprine; Budesonide; Calcium; Cannabidiol; Chloroquine; Chloroquine diphosphate; Chloroquine diphosphate 250mg; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine-A; Denosumab; EFALIZUMAB; Efalizumab; Erythropoietin; Gold; High protein high fiber diet; INTERLEUKIN 2; Ianalumab; Inflectra (Infliximab); Infliximab; Interleukin 2; JKB-122; JKB-122 in capsule or tablet form; LCP-Tacro (tacrolimus); MYCOPHENOLATE MOFETIL; Metronidazole; Minodronic acid; Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofeti; Mycophenolate mofetil; Orbcel-C; Orencia® (Abatacept); PREDNISOLONE SODIUM SUCCINATE; Prednisolone; Prednisone; Preimplantation factor; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Regulatory T cells; Risedronic acid; SPIF; Synthetic PreImplantation Factor; Tacrolimus; Treatment with azathioprin; Treatment with mycophenolat mofetil; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ursodeoxycholic acid combination of immunosuppressive agents; VAY736; Vitamin D; Zoledronic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00587119 (ClinicalTrials.gov)	December 2007	21/12/2007	Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis	Open-Label Pilot Study Evaluating Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis.	Primary Biliary Cirrhosis;Autoimmune Hepatitis	Drug: Budesonide	Mayo Clinic	NULL	Withdrawn	21 Years	75 Years	Both	0	N/A	United States
2	NCT00838214 (ClinicalTrials.gov)	March 2001	5/2/2009	Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis	Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-blind, Randomized, Active-controlled, Multicentre Study	Autoimmune Hepatitis	Drug: budesonide;Drug: prednisone	Dr. Falk Pharma GmbH	NULL	Completed	10 Years	70 Years	All	208	Phase 2;Phase 3	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00587119
(ClinicalTrials.gov)

December 2007

21/12/2007

Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis

Open-Label Pilot Study Evaluating Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis.

Primary Biliary Cirrhosis;Autoimmune Hepatitis

Drug: Budesonide

Mayo Clinic

NULL

Withdrawn

21 Years

75 Years

Both

N/A

United States

NCT00838214
(ClinicalTrials.gov)

March 2001

5/2/2009

Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-blind, Randomized, Active-controlled, Multicentre Study

Autoimmune Hepatitis

Drug: budesonide;Drug: prednisone

Dr. Falk Pharma GmbH

NULL

Completed

10 Years

70 Years

All

208

Phase 2;Phase 3

Germany